- Poster presentation
- Open Access
Effect of anemia on coagulation and platelet function: a whole blood in vitro study
© Scharbert et al. 2011
- Published: 1 March 2011
- Arachidonic Acid
- Platelet Aggregation
- Platelet Function
- Lowering Hemoglobin
- Adenosine Diphosphate
It is known that red blood cells are involved in hemostasis. They can support and improve coagulation in different ways. Therefore recommendations are given for red blood cell transfusions in anemic patients with massive bleeding to reach a hemoglobin concentration of 8 to 10 g/dl. Although blood transfusions can be life-saving, a number of negative or even potentially life-threatening effects are described.
In this study we investigated the effect of anemia on platelet function and plasmatic hemostasis with two different point-of-care methods: the multiple electrode aggregometry Multiplate® (MEA) and the rotational thrombelastometry ROTEM®. Blood was taken from 13 healthy volunteers to arrange in vitro anemia-series with 10, 7 and 3 g/dl hemoglobin. For the MEA we applied the agonists collagen, arachidonic acid, adenosine diphosphate (ADP), thrombin-receptor-activating peptide (TRAP) and ristocetin. For the ROTEM® analysis we used the tests EXTEM, INTEM and FIBTEM.
The MEA showed significantly increased velocity of platelet aggregation in anemic blood samples. The agonists TRAP and ADP demonstrated the highest effects. The Aggregation Units and the area under the curve were not influenced by anemia. The ROTEM® analysis displayed significantly an amplified maximum clot firmness (MCF), a shortened clot formation time (CFT) und an increased α-angle. The CFT and lysis index at 30 minutes did not show any changes through lowering hemoglobin. The calculated effect of platelets on ROTEM® coagulation (MCFplatelet = MCFEXTEM - MCFFIBTEM) was unchanged.
In our study platelet function in anemic blood was observed with the MEA for the first time. Our results showed accelerated platelet aggregation through lowering hemoglobin. Our findings of a hypercoagulable profile in ROTEM® are in accordance with earlier observations. Future clinical studies are needed to evaluate risk of bleeding or hypercoagulability in anemic patients.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.